The FDA has approved expanded premarket labeling for Abiomed's Impella 5.0 and Impella LD heart pumps, allowing them to be used for 14 days in patients with cardiogenic shock. The devices were previously approved for this indication for a duration of six days.
Abiomed wins expanded labeling from FDA for 2 heart pumps
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.